Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteome characterization of Breast Cancer Cell lines

ABSTRACT: Protein profiling of 18 breast cancer cell lines in triplicates using TMT10-plex.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Janne Lehtiö

PROVIDER: PXD013276 | JPOST Repository | Sat Jul 04 00:00:00 BST 2020

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Publications

PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.

Brunner Andrä A Suryo Rahmanto Aldwin A Johansson Henrik H Franco Marcela M Viiliäinen Johanna J Gazi Mohiuddin M Frings Oliver O Fredlund Erik E Spruck Charles C Lehtiö Janne J Rantala Juha K JK Larsson Lars-Gunnar LG Sangfelt Olle O

eLife 20200706

Inhibition of WEE1 kinase by AZD1775 has shown promising results in clinical cancer trials, but markers predicting AZD1775 response are lacking. Here we analysed AZD1775 response in a panel of human breast cancer (BC) cell lines by global proteome/transcriptome profiling and identified two groups of basal-like BC (BLBCs): 'PTEN low' BLBCs were highly sensitive to AZD1775 and failed to recover following removal of AZD1775, while 'PTEN high' BLBCs recovered. AZD1775 induced phosphorylation of DNA- ...[more]

PMID: 32628111

Similar Datasets

Effects of YB-1 protein reduction on microRNA abundance in breast cancer cell-lines

Project description:To assess the association of the nucleic acid binding protein yb-1 with mature microRNAs levels in breast cancer. To do this we performed YB-1 siRNA treatement in triplicates alongside an siRNA control Two breast cancer cell-lines, representative of Luminal A and Basal molecular subtypes were used, MCF7 and MDA-MB-435S.

2014-01-23 | GSE50087 | GEO

Effects of YB-1 protein reduction on microRNA abundance in breast cancer cell-lines

2014-01-23 | E-GEOD-50087 | biostudies-arrayexpress

A Combined Shotgun and Targeted Mass Spectrometry Strategy for Breast Cancer Biomarker Discovery

Project description:Metastasizing breast cancer is an incurable disease. Thus, it is important to find proteins responsible for tumor dissemination, which may be used as biomarkers or treatment targets. In this study, we established the combination of a non-targeted LC-MS/MS discovery and a targeted LC-SRM verification workflow for improved discovery and validation of biomarkers. We collected 80 breast tumors, stratified for estrogen receptor status and development of distant recurrence (DR+/-). After enrichment of N-glycosylated proteins, label-free LC-MS/MS was performed on all of the individual tumors in triplicates. In total, 1515 glycopeptides from 778 proteins were identified, used to create a map of the breast cancer N-glycosylated proteome. Based on the breast cancer N-glycosylated proteome map we constructed a 92-plex targeted label-free LC-SRM panel, enriched for interesting proteins, and analyzed the samples for the selected proteins, resulting in 10 proteins differentially regulated between DR+/DR- tumors. We also compared the LC-SRM results to clinically reported HER2 status. 17 of 18 patients could be classified the same way, demonstrating the clinical accuracy of LC-SRM. In conclusion, we demonstrated the use of a combined non-targeted LC-MS/MS and targeted LC-SRM strategy, at large scale on clinical samples, and identified 10 proteins as potential biomarkers.

2015-06-16 | PXD001685 | Pride

MicroRNA analysis of breast cancer cell lines

Project description:MicroRNA analysis of breast cancer cell lines

| PRJNA230102 | ENA

miRNA expression in breast cancer cell lines

Project description:miRNA expression in breast cancer cell lines

| PRJNA497259 | ENA

Breast Cancer Cell Lines

Project description:Gene expression analysis on growing breast cancer cell lines. Keywords: cancer cell line profiles

2005-11-07 | GSE3156 | GEO

MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection

Project description:We sought to build a catalog of epitopes presented by breast cancers using a renewable resource of well-characterized breast cancer cell lines. Starting from 70 breast cancer cell lines, we measured MHC class I abundance and used pre-existing RNAseq data to identify either HLA-A*02 or MHC class I-positive cell lines. For 20 of these cell lines, we used “reverse” immunogenetics, in which MHC class I-loaded peptides are recovered and their sequences are determined by mass spectrometry. We identified more than 2,700 unique MHC class I-bound peptides from a panel of basal, luminal, and claudin-low subtype of cell lines. HLA-A*02 binding prediction across all tested cell lines revealed a model which described the distribution of HLA-A*02-binding peptides and allowed us to identify those peptides most likely to be presented on HLA-A*02. Comparing the peptides that we identified to published literature found that more than 1500 peptides had been identified in previous studies and that 18 of these peptides have been shown to be immunogenic. Overall, this high throughput identification of MHC class I-loaded peptides is an effective strategy for systematic characterization of cancer epitopes and could be employed in a design of multipeptide-based anticancer vaccine.

2018-01-16 | PXD006406 | Pride

RIME against TRPS1 in breast cancer cell lines

Project description:Identification of TRPS1 interactors in MCF7, T47D and ZR75-1 breast cancer cell lines.

2018-06-12 | PXD009863 | Pride

VWCE inhibited the proliferation, migration, invasion, and chemoresistance of the breast cancer cell lines

Project description:Breast cancer remains a leading cause of cancer-related death, for which the majority of deaths result from metastases. Von Willebrand factor C and EGF domain (VWCE) is a member of the Von Willebrand factor (VWF) gene family; however, its function, regulatory mechanism, and clinical value in breast cancer remain unclear. In the present study, we sought to elucidate the role of VWCE in breast cancer metastasis. We examined the expression of VWCE in breast cancer tissues and normal control tissues of 50 breast cancer patients. We found that VWCE expression was downregulated in breast cancer cells and tissues compared to normal breast epithelial cells or the adjacent normal tissues. To explore the role of VWCE in human breast cancer development, we introduced a VWCE-overexpressing or control lentiviral vector into the breast cancer MDA-MB-453 and MDA-MB-231 lines in vitro. The overexpression of VWCE inhibited the proliferation, migration, invasion, and chemoresistance of the breast cancer cell lines. More import

2020-09-29 | PXD021733 | iProX

Breast Cancer Cell Lines

Project description:7 breast cancer cell lines were differentially labeled and each competitively hybridized against female genomic DNA using the 32K SMRT Array Keywords: None

2006-02-16 | GSE3106 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data